{
  "url": "https://openlegislation.uk/eu-regulation-1995-297/article-5",
  "json_url": "https://openlegislation.uk/eu-regulation-1995-297/article-5.json",
  "legislation": "eur/1995/297",
  "legislation_title": "Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products",
  "legislation_url": "https://openlegislation.uk/eu-regulation-1995-297",
  "path": "article/5",
  "kind": "article",
  "number": "5",
  "heading": "Medicinal products for veterinary use covered by the procedures laid down in Regulation (EC) No 726/2004",
  "text": "1.. Authorisation to market a medicinal product\n(a) Full fee\nA full fee of EUR 148 400 shall apply for an application for a marketing authorisation supported by a full dossier. That fee shall cover a single strength associated with one pharmaceutical form and one presentation.\nThe fee shall be increased by EUR 14 600 for each additional strength and/or pharmaceutical form submitted at the same time as the initial application for authorisation. That increase shall cover one additional strength or pharmaceutical form and one presentation.\nThe fee shall be increased by EUR 7 400 for each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.\nIn the case of immunological veterinary medicinal products, the full fee shall be reduced to EUR 73 800, with each additional strength and/or pharmaceutical form and/or presentation entailing an increase of EUR 7 400.\nFor the purposes of this point (a), the number of target species is irrelevant.\n(b) Reduced fee\nA reduced fee of EUR 73 800 shall apply to applications for a marketing authorisation pursuant to Article 13(1) and (3), and Article 13c of Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. That fee shall cover a single strength associated with one pharmaceutical form and one presentation.\nA specific reduced fee of EUR 125 300 shall apply to applications for a marketing authorisation pursuant to Article 13(4) of Directive 2001/82/EC. That fee shall cover a single strength associated with one pharmaceutical form and one presentation.\nThe reduced fees referred to in the first and second subparagraph shall be increased by EUR 14 600 for each additional strength or pharmaceutical form submitted at the same time as the initial application for authorisation. That increase shall cover one additional strength or pharmaceutical form and one presentation.\nThe reduced fees referred to in the first and second subparagraph shall be increased by EUR 7 400 for each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.\nIn the case of immunological veterinary medicinal products, the fee shall be reduced to EUR 37 100, with each additional strength and/or pharmaceutical form and/or presentation entailing an increase of EUR 7 400.\nFor the purposes of this point, the number of target species is irrelevant.\n(c) Extension fee\nAn extension fee of EUR 37 100 shall apply for each extension of a marketing authorisation within the meaning of Annex II to Regulation (EC) No 1085/2003, which has already been granted.\nBy derogation from the first subparagraph, a reduced extension fee falling withn the range of EUR 9 200 to EUR 27 900 shall apply for certain extensions. Those extensions shall be included in a list, which shall be drawn up in accordance with Article 11(2) of this Regulation.\nThe extension fee and the reduced extension fee shall be increased by EUR 7 400 for each additional presentation of the same extension submitted at the time of the extension application.\n2.. Variation\n(a) Type I variation fee\nA Type I variation fee shall apply for a minor variation to a marketing authorisation, as defined in Article 3(2) of Regulation (EC) No 1085/2003. For Type IA variations, the fee shall be EUR 3 300. For Type IB variations, the fee shall be EUR 7 400.\nIn the event of the same variation being introduced, this fee shall cover all authorised strengths, pharmaceutical forms and presentations.\n(b) Type II variation fee\nA Type II variation fee of EUR 44 400 shall apply for a major variation to a marketing authorisation, as defined in Article 3(3) of Regulation (EC) No 1085/2003.\nBy derogation from the first subparagraph, a reduced Type II variation fee falling within the range of EUR 11 200 to EUR 33 500 shall apply for certain variations. Those variations shall be included in a list, which shall be drawn up in accordance with Article 11(2) of this Regulation.\nIn the case of immunological veterinary medicinal products, the fee shall be EUR 7 400.\nIn the event of the same variation being introduced, the fee referred to in the first, second and third subparagraph shall cover all authorised strengths, pharmaceutical forms and presentations.\n3.. Renewal fee\nThe fee for examining information available at the time of the five-yearly renewal of an authorisation to market a medicinal product shall be EUR 7 400. It shall be charged for each strength associated with a pharmaceutical form.\n4.. Inspection fee\nA fee of EUR 22 400 shall apply for any inspection within or outside the Community. For inspections outside the Community, travel expenses shall be charged extra on the basis of actual cost.\nBy derogation from the first subparagraph, a reduced inspection fee shall apply for certain inspections, according to the extent and nature of the inspection and on the basis of the conditions laid down in accordance with Article 11(2).\n5.. Transfer fee\nThe fee for a change in the holder of the marketing authorisations to which the transfer relates shall be EUR 7 400. This covers all authorised presentations of a given medicinal product.\n6.. Annual fee\nAn annual fee of EUR 35 600 shall apply for each marketing authorisation of a medicinal product. That fee shall cover all authorised presentations of a given medicinal product.\nBy derogation from the first subparagraph, a reduced annual fee falling within the range of EUR 8 700 to EUR 26 400 shall apply for certain types of medicinal products. Those medicinal products shall be included in a list, which shall be drawn up in accordance with Article 11(2).",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Inserted by Council Regulation (EC) No 2743/98 of 14 December 1998."
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Substituted by Council Regulation (EC) No 1905/2005 of 14 November 2005 amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency."
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Substituted by Commission Regulation (EU) 2020/422 of 19 March 2020 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2020 (Text with EEA relevance)."
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Inserted by Council Regulation (EC) No 1905/2005 of 14 November 2005 amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency."
    },
    {
      "type": "footnote",
      "label": "f1",
      "text": "OJ L 311, 28.11.2001, p. 1 . Directive as last amended by Directive 2004/28/EC ( OJ L 136, 30.4.2004, p. 58 )."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/1995/297/article/5",
    "retrieved_at": "2026-11-01T14:59:48.109940+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}